Updated:
quadraScope
quadraScope Ventures: Fiona Miller's firm backs early-stage longevity biotechs targeting aging hallmarks.
quadraScope
quadraScope invests in early-stage companies developing pharmaceuticals, diagnostics, software, equipment and devices enabling biological age reversal, disease treatment, prevention and longevity.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
Tel Aviv, Israel
Principals
Fiona Miller
Operating Team
José Navarro-Betancourt
Operating Team
Eve Voronkina
Operating Team
Nir Barzilai
Scientific Advisory Board
Aubrey de Grey
Scientific Advisory Board
Carmela Abraham
Scientific Advisory Board
Robert Cargill
Scientific Advisory Board
Diane Seimetz
Scientific Advisory Board
Reason
Scientific Advisory Board
Nikola Markov
Scientific Advisory Board
Miri Polachek
Business Advisory Board
Nico Helling
Business Advisory Board
Frank Wellens
Business Advisory Board
Daniel Fylstra
Business Advisory Board
Lan Clark
Business Advisory Board
José Cordeiro
Business Advisory Board
Noriko Yokoi
Business Advisory Board
Sector focus
Frequently asked questions
Who runs investment decisions at quadraScope?
Fiona Miller leads the firm, alongside operating team members José Navarro-Betancourt, MD, PhD, and Eve Voronkina. The firm also draws on a scientific advisory board that includes Nir Barzilai, MD, and Aubrey de Grey, PhD, to guide investment selection. Business advisory input comes from Miri Polachek and others.
How does quadraScope source proprietary deal flow?
quadraScope cites strategic locations in Boston and Tel Aviv to leverage concentrations of biotech academia and industry. The firm also points to its scientific advisory board, which includes prominent geroscientists, as a filter for early-stage deal vetting.
Is quadraScope structured as a single family office or does it operate more like a venture firm?
quadraScope operates as an asset manager with a private equity structure, not a single-family office. It functions as a venture firm making direct early-stage investments.
Does quadraScope participate in fund commitments or only direct deals?
Available public information describes quadraScope's activity exclusively in terms of direct deals into early-stage companies. Its website does not mention fund-of-funds commitments or co-investment vehicles.
What investment stages does quadraScope typically target?
quadraScope targets early-stage companies, specifically Seed and Start-up stages. It puts capital into ventures developing pharmaceuticals, diagnostics, software, equipment, and devices for the longevity sector.
How is quadraScope related to Repair Biotechnologies or Longevity Escape Velocity Foundation?
Reason, CEO of Repair Biotechnologies, serves on quadraScope's scientific advisory board and refers to the firm as an investor in his company. Aubrey de Grey, who also serves on the scientific advisory board, is President and CSO of the Longevity Escape Velocity Foundation and notes that he serves because of the quality of quadraScope's investment choices, including into his organizations.
What is quadraScope's known posture on co-investments alongside external GPs?
quadraScope does not publicly discuss co-investment alongside external GPs. Its disclosed investment model is direct investing into early-stage longevity companies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: